GETI.B

192.5

-0.41%↓

ATT

104.7

-1.04%↓

AMBEA

139.7

+1.16%↑

ARJOB

24.72

-1.36%↓

MSON.B

+1.69%↑

GETI.B

192.5

-0.41%↓

ATT

104.7

-1.04%↓

AMBEA

139.7

+1.16%↑

ARJOB

24.72

-1.36%↓

MSON.B

+1.69%↑

GETI.B

192.5

-0.41%↓

ATT

104.7

-1.04%↓

AMBEA

139.7

+1.16%↑

ARJOB

24.72

-1.36%↓

MSON.B

+1.69%↑

GETI.B

192.5

-0.41%↓

ATT

104.7

-1.04%↓

AMBEA

139.7

+1.16%↑

ARJOB

24.72

-1.36%↓

MSON.B

+1.69%↑

GETI.B

192.5

-0.41%↓

ATT

104.7

-1.04%↓

AMBEA

139.7

+1.16%↑

ARJOB

24.72

-1.36%↓

MSON.B

+1.69%↑

Home・Akciju saraksts・Elekta AB

Elekta AB

Slēgts

54.45 0.37

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

53.75

Max

54.95

Galvenie mērījumi
By Trading Economics
Ienākumi	-220M 10M
Pārdošana	169M 4.2B
P/E Sektora vidējais	74.079 60.328
EPS	0.88
Dividenžu ienesīgums	4.2
Peļņas marža	0.236
Darbinieki	4,438
EBITDA	111M 640M

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	4.20% 2.24%
Nākamie ieņēmumi	2026. g. 28. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	432M 22B
Iepriekšējā atvēršanas cena	54.08
Iepriekšējā slēgšanas cena	54.45

Elekta AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026. g. 27. apr. 23:08 UTC

Peļņas

Galvenie tirgus virzītāji

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026. g. 27. apr. 23:48 UTC

Tirgus saruna

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 27. apr. 23:42 UTC

Tirgus saruna

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026. g. 27. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026. g. 27. apr. 23:30 UTC

Tirgus saruna

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026. g. 27. apr. 23:08 UTC

Tirgus saruna

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026. g. 27. apr. 22:42 UTC

Tirgus saruna

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026. g. 27. apr. 22:10 UTC

Peļņas

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026. g. 27. apr. 21:56 UTC

Peļņas

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026. g. 27. apr. 21:44 UTC

Peļņas

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026. g. 27. apr. 21:43 UTC

Peļņas

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. apr. 20:39 UTC

Peļņas

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Salīdzinājums

Cenas izmaiņa

Elekta AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.